Equity Profile

KOD

Kodiak Sciences Inc.

Health CareBiotechnology$1.9B

May7Thu

Post-Earnings Recap

ReportedQ1-2026After Close4:00 PM EDT

Kodiak Sciences Misses on EPS, Stock Down 4.82%

Metric	Actual	Expected	Surprise
EPS	$-0.94	N/A	-1.29%
Revenue	N/A	N/A	N/A

management commentary, guidance changes, and full analysis available with Pro.

Kodiak Sciences Misses on EPS, Stock Down 4.82%

Key Numbers

Metric	Actual	Expected	Surprise
EPS	$-0.94	N/A	-1.29%
Revenue	N/A	N/A	N/A

Management Commentary

Tone: Unknown

No transcript is on record, and the analysis is based solely on numerical results.

What It Means

Kodiak Sciences reported a loss of $0.94 per share, slightly missing expectations. The stock reacted negatively, dropping 4.82%. Investors may be concerned about the lack of revenue information and guidance, which could indicate uncertainty about the company's future performance.

Company Snapshot

Kodiak Sciences Inc. is a biotechnology company focused on developing treatments for eye diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth is crucial for assessing the company's market performance and demand for its products.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Kodiak Sciences Inc. is a biotechnology company focused on developing treatments for eye diseases. With a market cap of $3 billion, it operates in the health care sector, which is increasingly important as the global population ages and the demand for innovative medical solutions grows.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

-3.44%

Avg Stock Reaction

-0.51%

Last Quarter Recap

In the last quarter, Kodiak reported an EPS of -$1.04, slightly missing analyst expectations. The stock reacted positively, gaining 13.25% the following day, indicating some investor optimism despite the loss.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations for Kodiak's upcoming earnings are uncertain due to a lack of analyst estimates. Investors are keen to see if the company can improve its financial performance and provide clarity on its product pipeline.

Bull Case

If Kodiak can demonstrate significant progress in its clinical trials and report better-than-expected EPS, it could lead to a strong rally in the stock price, reflecting renewed investor confidence.

Bear Case

Conversely, if the company reports wider losses or delays in its product pipeline, it may lead to a negative reaction from investors, driving the stock down.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the current status of Kodiak's clinical trials for its leading product candidates?

Investors will closely watch for updates on clinical trials, as successful results could significantly boost the stock price.

How does Kodiak plan to address its ongoing losses and improve profitability?

Management's strategy for reducing losses and achieving profitability will be crucial for investor confidence and stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for Kodiak's pipeline to deliver breakthrough results, which could lead to a significant upside.

Supporting Evidence

The options market is pricing in a 13.1% move, indicating expectations for volatility that may not align with the company's actual performance.

Kodiak's recent stock price movements suggest a level of investor optimism that could be overlooked by analysts.

Key Risk

If clinical trial results exceed expectations, it could shift the narrative dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around the company's ability to turn clinical advancements into financial performance.

Bull Confirmed If

A report of positive clinical trial results for its leading product candidates could confirm the bull case.

Bear Confirmed If

Wider-than-expected losses or delays in product development could confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±13.1%

Historical Avg

±4.5%

Pricing rich

The options market is pricing in a significant move of about 13.1%, suggesting that traders expect volatility around the earnings report.

Options are pricing ±10.2% while KOD has averaged ±4.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

182.4%

Calls (11K)P/C Ratio: 0.90Puts (6K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Kodiak beats expectations and raises guidance, history suggests a potential stock increase of around 1.34% on the following day.

In-Line / Cautious

If results are in line with expectations but cautious commentary is provided, the stock may see muted movement.

Miss

If Kodiak misses expectations, history suggests a potential decline of about 1.81% the next day.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the progress of clinical trials for key products.
2Any guidance on future revenue expectations or cost management strategies.
3Details on partnerships or collaborations that could enhance product development.
4Management's outlook on the competitive landscape in the biotechnology sector.
5Insights into the company's long-term strategy for achieving profitability.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

May4

FANGReported

Diamondback Energy, Inc.

RecapView

May4

OSISReported

Company Snapshot

Kodiak Sciences Inc. is a biotechnology company focused on developing treatments for eye diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth is crucial for assessing the company's market performance and demand for its products.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

-3.44%

Avg Stock Reaction

-0.51%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Kodiak can demonstrate significant progress in its clinical trials and report better-than-expected EPS, it could lead to a strong rally in the stock price, reflecting renewed investor confidence.

Bear Case

Conversely, if the company reports wider losses or delays in its product pipeline, it may lead to a negative reaction from investors, driving the stock down.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the current status of Kodiak's clinical trials for its leading product candidates?

Investors will closely watch for updates on clinical trials, as successful results could significantly boost the stock price.

How does Kodiak plan to address its ongoing losses and improve profitability?

Management's strategy for reducing losses and achieving profitability will be crucial for investor confidence and stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for Kodiak's pipeline to deliver breakthrough results, which could lead to a significant upside.

Supporting Evidence

The options market is pricing in a 13.1% move, indicating expectations for volatility that may not align with the company's actual performance.

Kodiak's recent stock price movements suggest a level of investor optimism that could be overlooked by analysts.

Key Risk

If clinical trial results exceed expectations, it could shift the narrative dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around the company's ability to turn clinical advancements into financial performance.

Bull Confirmed If

A report of positive clinical trial results for its leading product candidates could confirm the bull case.

Bear Confirmed If

Wider-than-expected losses or delays in product development could confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±13.1%

Historical Avg

±4.5%

Pricing rich

The options market is pricing in a significant move of about 13.1%, suggesting that traders expect volatility around the earnings report.

Options are pricing ±10.2% while KOD has averaged ±4.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

182.4%

Calls (11K)P/C Ratio: 0.90Puts (6K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Kodiak beats expectations and raises guidance, history suggests a potential stock increase of around 1.34% on the following day.

In-Line / Cautious

If results are in line with expectations but cautious commentary is provided, the stock may see muted movement.

Miss

If Kodiak misses expectations, history suggests a potential decline of about 1.81% the next day.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the progress of clinical trials for key products.
2Any guidance on future revenue expectations or cost management strategies.
3Details on partnerships or collaborations that could enhance product development.
4Management's outlook on the competitive landscape in the biotechnology sector.
5Insights into the company's long-term strategy for achieving profitability.